Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.

[1]  M. Boyano,et al.  Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma , 2000, British Journal of Cancer.

[2]  L. Parvinen,et al.  The value of serum S‐100&bgr; and interleukins as tumour markers in advanced melanoma , 2000, Melanoma research.

[3]  A. Heiligenhaus,et al.  Expression of the Cell Adhesion Molecules ICAM-1, VCAM-1 and NCAM in Uveal Melanoma: A Clinicopathological Study , 2000, Oncology.

[4]  A. Hauschild,et al.  S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma , 1999, Oncology.

[5]  J. Lawry,et al.  The correlation between cell surface markers and clinical features in choroidal malignant melanomas , 1999, Eye.

[6]  Jun Chen,et al.  Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1 , 1999, Journal of Cancer Research and Clinical Oncology.

[7]  M. Probst-Kepper,et al.  Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. , 1998, British Journal of Cancer.

[8]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[9]  E. Brown,et al.  Cross talk between αvβ3 and α4β1 integrins regulates lymphocyte migration on vascular cell adhesion molecule 1 , 1997 .

[10]  S. Ferrini,et al.  Role of interleukin (IL)-2 and IL‐15 in the tumour progression of a melanoma cell line MELP, derived from an IL‐2 progressor patient , 1997, Melanoma research.

[11]  L. Hansson,et al.  Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. , 1997, Anticancer research.

[12]  M. Boyano,et al.  Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. , 1997, Oncology.

[13]  K. Wakamatsu,et al.  Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma , 1997, Melanoma research.

[14]  C. Garbe,et al.  Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma , 1997, Melanoma research.

[15]  Caligiuri Ma,et al.  Molecular biology of acute myeloid leukemia. , 1997 .

[16]  P. Philip,et al.  Treatment of malignant melanoma with interleukin-2. , 1997, Seminars in oncology.

[17]  L. Hansson,et al.  Prognostic value of serum analyses of S‐100β protein in malignant melanoma , 1996 .

[18]  L. Misery,et al.  Follow‐up of circulating ICAM‐1 in malignant melanoma: correlation with the clinical course of the disease , 1996, The British journal of dermatology.

[19]  D. Schadendorf,et al.  Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. , 1996, Dermatology.

[20]  N. Kernohan,et al.  Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumour cells in situ and in vitro: Evidence for a direct role in the regulation of tumour cell proliferation , 1995, International journal of cancer.

[21]  B. Imhof,et al.  Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma , 1995, The Journal of experimental medicine.

[22]  R. Banks,et al.  Cytokines as tumour markers. , 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[23]  L. Trentin,et al.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. , 1994, British Journal of Cancer.

[24]  S. Ferrone,et al.  Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. , 1993, Cancer research.

[25]  S. Albelda,et al.  Role of integrins and other cell adhesion molecules in tumor progression and metastasis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[26]  S. Bernasconi,et al.  Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma. , 1992, The American journal of pathology.

[27]  S. J. Cashman,et al.  Soluble Forms of Vascular Adhesion Molecules, E‐Selectin, ICAM‐1, and VCAM‐1: Pathological Significance , 1992, Annals of the New York Academy of Sciences.

[28]  M. Maio,et al.  Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. , 1992, The New England journal of medicine.

[29]  B. Østenstad.  Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer. , 1992 .

[30]  M. Bernengo,et al.  Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study. , 1992, Dermatology.

[31]  R. Rothlein,et al.  Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. , 1991, Cancer research.

[32]  G. Rice,et al.  Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. , 1991, The American journal of pathology.

[33]  L A Rubin,et al.  The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.

[34]  S. Ferrone,et al.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.

[35]  G. Rice,et al.  An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. , 1989, Science.